10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance  for Truxima (rituximab), the first biosimilar to Rituxan (rituximab) in Canada for the treatment of adult patients in: non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis.

"Biosimilars are a new chapter in the therapeutic oncology setting in Canada and represent a growing focus for Teva since they will allow us to increase access to important therapeutic options," said Christine Poulin, Senior Vice President and General Manager of Teva Canada. "Moreover, Teva's biosimilars will have the potential to reduce costs by providing lower-cost treatment options for patients."

First approved in South Korea in November 2016, Truxima was approved by regulatory authorities including the European Commission in 2017 and the FDA in 2018 for certain indication in the U.S. This announcement establishes Teva's position in the biosimilars space and leverages its existing expertise in the oncology market.

Read Teva Pharmaceuticals press release